Otsuka, Click Therapeutics get FDA clearance for prescription digital therapeutic
Otsuka Pharmaceuticals and Click Therapeutics announced that Rejoyn, a smartphone-based prescription digital therapeutic for major depressive disorder (MDD), scored FDA clearance to be used as an adjunct to clinician-managed care. Rejoyn is a six-week remote…
Continue Reading